## Poly Medicure Limited (POLYMED) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Poly Medicure Limited (POLYMED) is a company operating in the Medical Equipment & Supplies industry.  It was listed on the NSE on December 7, 2011.  Further information on its specific market positioning within the sector would require additional research beyond the provided data.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹2,566.45       |                                                                      |
| Percentage Change (PChange) | -3.30%          | Significant negative daily change.                                   |
| Pre-Open Activity          | ₹2,676.65       |  Positive pre-open activity, suggesting potential buying interest.     |
| Week High                    | ₹3,357.80       | Significant high compared to current price, indicating recent volatility.|
| Week Low                     | ₹1,361.00       | Significant low compared to current price, indicating recent volatility.|
| VWAP                        | ₹2,626.33       | Volume Weighted Average Price slightly higher than current price.      |
| Sector PE                   | 91.87           | High sector Price-to-Earnings ratio.                               |
| Symbol PE                   | 91.87           | High Price-to-Earnings ratio for POLYMED.                           |
| Delivery Percentage         | 48.78%          | Moderate delivery percentage; a portion of trades were delivery-based.|
| Market Depth                | Low              |  The provided market depth data (total buy/sell quantity = 0) is insufficient for a proper analysis. Further data is needed. |


**3. Financial Performance:**

The provided financial data shows a consistent profit after tax and positive EPS over the past five quarters. However, it's crucial to note that these are unaudited figures for the most recent quarters.

| Quarter      | Revenue (₹)     | Expenses (₹)    | Profit After Tax (₹) | EPS (₹) |
|--------------|-----------------|-----------------|-----------------------|---------|
| Q3 FY25 (Sep) | 42,971.31       | 31,278.36       | 8,722.04              | 8.99    |
| Q2 FY25 (Jun) | 38,425.62       | 28,818.09       | 7,230.25              | 7.53    |
| Q1 FY25 (Mar) | 37,658.75       | 28,261.52       | 7,053.25              | 7.35    |
| Q4 FY24 (Dec) | 33,742.84       | 25,533.87       | 6,146.08              | 6.41    |
| Q3 FY24 (Sep) | 33,268.20       | 25,471.81       | 5,920.59              | 6.17    |


**Key Financial Ratios:**  Further analysis requires additional financial statements to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, and others.  The provided data only shows profit and EPS.


**4. Corporate Actions and Announcements:**

Recent corporate actions include consistent dividend payouts (₹3 per share in Sep 2024 and Sep 2023, ₹2.50 in Sep 2022, etc.).  Several announcements relate to board meetings, financial results, and loss/duplicate share certificates.  No significant negative announcements are immediately apparent.

**5. Shareholding Patterns:**

| Date        | Promoter & Promoter Group (%) | Public (%) | Employee Trusts (%) | Total (%) |
|-------------|-----------------------------|------------|--------------------|-----------|
| 31-Dec-2023 | 53.16                       | 46.84      | 0.00                | 100.00    |
| 31-Mar-2024 | 53.15                       | 46.85      | 0.00                | 100.00    |
| 30-Jun-2024 | 66.03                       | 33.97      | 0.00                | 100.00    |
| 22-Aug-2024 | 62.56                       | 37.44      | 0.00                | 100.00    |
| 30-Sep-2024 | 62.56                       | 37.44      | 0.00                | 100.00    |

A significant increase in promoter holding is observed between March and June 2024.  This could be a positive sign, but further investigation into the reason for this increase is warranted.


**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low.  The CM Annual Volatility of 50.82% further confirms this.  The risk-reward profile is currently high risk due to volatility and the lack of sufficient market depth data.

**7. Advantages of Buying the Stock:**

* Consistent profitability and positive EPS over the past five quarters.
* Regular dividend payouts.
* Significant increase in promoter holding (requires further investigation).

**8. Disadvantages and Risks:**

* High volatility and significant price swings.
* Insufficient market depth data hinders accurate risk assessment.
* Reliance on unaudited financial data for the most recent quarters.
* High PE ratio compared to the sector.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The recent price drop and high volatility make a short-term buy risky.  Holding allows for monitoring of market trends and potential short-term triggers.

* **Medium-term (3 to 12 months): Hold.**  The consistent profitability and dividend payouts are positive, but the volatility remains a concern.  Monitoring financial performance and industry trends is crucial.

* **Long-term (1 year and beyond): Hold with caution.**  The fundamentals appear reasonably strong, but the high volatility and lack of comprehensive data necessitate caution.  Further research is needed to assess long-term growth potential.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* Financial health: 7/10 (Consistent profitability, but unaudited data and high PE ratio are concerns).
* Market performance: 5/10 (High volatility, negative recent price movement).
* Volatility and risk: 4/10 (High volatility, insufficient market depth data).
* Corporate actions and governance: 8/10 (Consistent dividends, but some announcements regarding share certificates).
* Shareholding patterns: 7/10 (Increased promoter holding is positive, but requires further investigation).

**Analysis Score (out of 10): 7/10**

* Completeness and utilization of all provided data: 8/10 (Most data used effectively, but some limitations).
* Accuracy and clarity of the analysis: 7/10 (Analysis is clear, but some aspects require further data).
* Professional formatting: 8/10 (Report is well-structured and easy to read).


**11. Professional Recommendation Summary:**

Based on the available data, POLYMED presents a mixed picture. While consistent profitability and dividend payouts are positive, the high volatility and insufficient market depth data raise significant concerns.  A "Hold" recommendation is given across all investment horizons, pending further investigation into the reasons behind the increased promoter holding and a more comprehensive market depth analysis.  Investors should carefully monitor the stock's performance and any new developments before making any investment decisions.  Additional research is strongly recommended.
